Reviewer: S. Randhawa, M.D., Allergist/Immunologist and Assistant Professor at LSU (Shreveport) Department of Allergy and Immunology
IL-12 family cytokines are immunological playmakers that mediate surprisingly diverse functional effects (Nature, 2012 http://buff.ly/PE2xeG).
Source: Macrophages, dendritic cells
Crystal structure of human IL-12, Wikipedia, public domain.
IL-12 effects
- T cells: TH1 differentiation
- NK cells and T cells: IFN-γ synthesis, increased cytotoxic activity
IL-12 is the main cytokine that activates STAT4.
IL-12 consists of two subunits - p35 and p40.
IL-12 binds to a type I receptor, composed of β1 and β2 subunits:
- p35 binds to β2 receptor, leading to Jak 2 activation and STAT4
- p40 binds to β1 receptor, leading toTyk 2 activation and STAT4
IL-12 sends a powerful signal to naive T cells, directing their differentiation to TH, shifting immune response towards cell-mediated immunity. In asthma, production of IL-12 by blood cells and expression in airway is impaired.
IL-18 is synergistic with IL-12.
Injection of rh IL-12 reduces circulating eosinophils in asthma. Treatment was not well tolerated: flu-like symptoms, abnormal LFTs and arrhythmias. Not actively developed as a therapy.
References
Bryan, SA, O'Connor, BJ, Matti, S, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2149.
Trials
Injection of rh IL-12 reduces circulating eosinophils in asthma. Treatment was not well tolerated: flu-like symptoms, abnormal LFTs and arrhythmias. Not actively developed as a therapy.
References
Bryan, SA, O'Connor, BJ, Matti, S, et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2149.
Related reading
IL-12 in Wikipedia.
Ustekinumab is a Strong Option for Moderate to Severe Psoriasis - anti-IL12/23 monoclonal antibody with NNT of 2 http://goo.gl/gbXSJ
Published: 04/09/2010
Updated: 08/09/2011
Published: 04/09/2010
Updated: 08/09/2011
No comments:
Post a Comment